Edwards Lifesciences EW United States — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's united states — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's united states — cost of sales?
- Edwards Lifesciences (EW) reported united states — cost of sales of $172M in Q1 2026.
- How has Edwards Lifesciences's united states — cost of sales changed year-over-year?
- Edwards Lifesciences's united states — cost of sales increased by 17.8% year-over-year, from $146M to $172M.
- What is the long-term trend for Edwards Lifesciences's united states — cost of sales?
- Over 3 years (2022 to 2025), Edwards Lifesciences's united states — cost of sales has grown at a 14.0% compound annual growth rate (CAGR), from $418.9M to $620.3M.
- What does united states — cost of sales mean?
- This metric captures the direct costs associated with manufacturing and delivering medical devices sold within the United States. It includes raw materials, labor, and overhead directly attributable to the production of heart valves and related surgical equipment. Monitoring this cost helps evaluate the efficiency of the domestic supply chain and manufacturing processes.